ALCEDIAG

Biomarker-based diagnostics for Mental Health ALCEDIAG is a personalized medicine company specializing in the development of biological signatures aimed to serve as the basis of diagnostics tools, with a primary focus on mental health. These biomarkers are based on the analysis of RNA editing, an epigenetic mechanism altering the nature and conformation of RNA. RNA editing may lead to the production of altered forms of proteins or modify gene expression regulation. RNA editing can be modified in the case of certain diseases, or as a consequence of a medical treatment. ALCEDIAG blood biomarkers already have been proven to be related to mental health conditions such as depression and suicidal tendencies. ALCEDIAG develops EDITDIAG, a blood test to diagnose mental disorders. EDITDIAG has already been clinically tested, showing outstanding sensitivity and specificity, on hundreds of patients and for several pathologies including depression, suicidal tendencies and bipolar disorders. Based on its expertise and experience, ALCEDIAG also developed a platform to discover new biomarkers based on RNA editing. The company exploits this platform for the needs of its own tests and research and collaborates with other entities to discover biomarkers for other pathologies. ALCEDIAG commercializes EDITOX, a predictive test to assess neuropsychiatric adverse effects. EDITOX assesses the risk for drugs to induce severe psychiatric side effects, with a first focus on depression and suicide and then on epilepsy. ALCEDIAG is a subsidiary of Alcen, an industrial group active in the domains of medical & healthcare, defense & security, aeronautics & space, energy and large scientific instruments. ALCEDIAG is currently looking for partners to develop companion diagnostic tests for mental health. Headquarters: Route des Michels CD 56, 13270 Peynier - France R&D: Parc Euromedecine, Cap Delta, 1682 rue de la Valsière, 34184 Montpellier – France